Inspira Tech to Report Blood Oxygenation Results Soon

Ticker: IINNW · Form: 6-K · Filed: Mar 4, 2024 · CIK: 1837493

Inspira Technologies Oxy B.H.N. LTD 6-K Filing Summary
FieldDetail
CompanyInspira Technologies Oxy B.H.N. LTD (IINNW)
Form Type6-K
Filed DateMar 4, 2024
Risk Levelmedium
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: medical-technology, results-announcement, respiratory-care

TL;DR

Inspira Tech dropping core blood oxygenation tech results any day now.

AI Summary

Inspira Technologies Oxy B.H.N. Ltd. announced on March 4, 2024, that it plans to report primary results for its core blood oxygenation technology within days. This technology aims to provide a temporary solution for patients suffering from respiratory failure, potentially reducing the need for invasive mechanical ventilation.

Why It Matters

The results could indicate a significant advancement in respiratory support technology, potentially offering a less invasive alternative to current life-saving treatments for respiratory failure.

Risk Assessment

Risk Level: medium — The company is announcing upcoming results, but the actual success and market adoption of the technology are still uncertain.

Key Players & Entities

FAQ

What is the specific technology Inspira Technologies is reporting results for?

The filing states it is for their 'core blood oxygenation technology'.

When can investors expect these results to be announced?

The press release, furnished as Exhibit 99.1, indicates the results will be reported 'within days' of March 4, 2024.

What is the potential benefit of this technology?

The technology aims to provide a temporary solution for patients suffering from respiratory failure, potentially reducing the need for invasive mechanical ventilation.

What form is this filing?

This is a Form 6-K, a report of foreign private issuer.

What is the company's principal executive office address?

The address is 2 Ha-Tidhar St. Ra'anana 4366504, Israel.

Filing Stats: 302 words · 1 min read · ~1 pages · Grade level 8.8 · Accepted 2024-03-04 09:25:02

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Inspira Technologies Oxy B.H.N. Ltd. Date: March 4, 2024 By: /s/ Dagi Ben-Noon Name: Dagi Ben-Noon Title: Chief Executive Officer 2

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing